EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon, D Ross Camidge, Jessica J Lin, Sang-We Kim, Benjamin J Solomon, Rafal Dziadziuszko, Benjamin Besse, Koichi Goto, Adrianus Johannes de Langen, Jürgen Wolf, Ki Hyeong Lee, Sanjay Popat und 22 weitere

New England Journal of Medicine · 11.01.2024 · 390 (2) · 118-131

DOI: 10.1056/nejmoa2302299 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 11.01.2024. Verfasst von Alexander Drilon und 33 weiteren Autor:innen. Beteiligte Einrichtung: From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (A.D.) and the NYU Perlmutter Cancer Center (V.V.) - all in New York; t…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein-Tyrosine Kinases, Antineoplastic Agents. Die Arbeit wurde bisher 254-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Manchester Biomedical Research Centre, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein-Tyrosine KinasesAntineoplastic AgentsHumansProto-Oncogene ProteinsTreatment OutcomePyrazolesMacrocyclic Compounds

Substanzen

Protein-Tyrosine KinasesProto-Oncogene ProteinsAntineoplastic AgentsrepotrectinibPyrazolesMacrocyclic CompoundsROS1 protein, human

Autor:innen und Institutionen

  • From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (A.D.) and the NYU Perlmutter Cancer Center (V.V.) - all in New York; the University of Colorado, Anschutz Medical Campus, Aurora (D.R.C.); M…

Förderung

  • NCI NIH HHS
  • Manchester Biomedical Research Centre
  • National Cancer Institute
  • Bristol-Myers Squibb

Zitieren

APA

Drilon, A., Camidge, D. R., Lin, J. J., Kim, S. W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., Lee, K. H., Popat, S., Springfeld, C., Nagasaka, M., Felip, E., Yang, N., Velcheti, V., Lu, S., Kao, S., …, & TRIDENT-1 Investigators (2024). Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 390(2), 118-131. https://doi.org/10.1056/nejmoa2302299

Vancouver

Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, et al. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2024;390(2):118-131. doi:10.1056/nejmoa2302299

BibTeX
@article{Drilon2024,
  author = {Drilon, Alexander and Camidge, D Ross and Lin, Jessica J and Kim, Sang-We and Solomon, Benjamin J and Dziadziuszko, Rafal and Besse, Benjamin and Goto, Koichi and de Langen, Adrianus Johannes and Wolf, Jürgen and Lee, Ki Hyeong and Popat, Sanjay and Springfeld, Christoph and Nagasaka, Misako and Felip, Enriqueta and Yang, Nong and Velcheti, Vamsidhar and Lu, Shun and Kao, Steven and Dooms, Christophe and Krebs, Matthew G and Yao, Wenxiu and Beg, Muhammad Shaalan and Hu, Xiufeng and Moro-Sibilot, Denis and Cheema, Parneet and Stopatschinskaja, Shanna and Mehta, Minal and Trone, Denise and Graber, Armin and Sims, Gregory and Yuan, Yong and Cho, Byoung Chul and TRIDENT-1 Investigators, TRIDENT-1 Investigators},
  title = {Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {2},
  pages = {118--131},
  doi = {10.1056/nejmoa2302299}
}
Kostenlos starten →